Monday July 6, 2020

Elan begins Down syndrome drug trial

Dublin-listed pharma company Elan has announced the first patient dosing in a Phase 2a study of a drug that could be used by people with Down syndrome.

4th September, 2013
Elan.

Dublin-listed pharma company Elan has announced the first patient dosing in a Phase 2a study of a drug that could be used by people with Down syndrome.

Drug development efforts in this area have been limited so far and there are currently no drugs approved for the treatment of cognitive dysfunction in Down syndrome. Elan’s ELND005 compound is being studied to see if it has potential as a cognitive enhancer that may improve everyday functioning...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 6 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago